APO Research
Talk to an analyst

APO RESEARCH · REPORT

Mirabegron Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Mirabegron Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025194 pages

Choose your research edition.

Industry ResearchMirabegron Drugs Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Mirabegron Drugs Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Mirabegron Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Mirabegron Drugs Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Mirabegron Drugs Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Mirabegron Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Mirabegron Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Mirabegron Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Mirabegron Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Mirabegron Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Mirabegron Drugs include Alkem Laboratories, Astellas Pharma, Lupin Pharmaceuticals, Zydus Lifesciences, China Resources Pharmaceutical, Jiangsu Huayang Pharmaceutical, Jiangxi Shanxiang Pharmaceutical, Qilu Pharmaceutical and Shenzhen Main Luck Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Mirabegron Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Mirabegron Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Mirabegron Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Mirabegron Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Mirabegron Drugs Segment by Company

Alkem Laboratories

Astellas Pharma

Lupin Pharmaceuticals

Zydus Lifesciences

China Resources Pharmaceutical

Jiangsu Huayang Pharmaceutical

Jiangxi Shanxiang Pharmaceutical

Qilu Pharmaceutical

Shenzhen Main Luck Pharmaceuticals

CSPC Pharmaceutical

Sichuan Gowell Pharmaceutical

Zhejiang Huayi Pharmaceutical

Chia Tai Tianqing Pharmaceutical

Mirabegron Drugs Segment by Type

Extended-release Tablet

Oral Suspension

Mirabegron Drugs Segment by Application

Frequent Urination

Urgency

Urine Leakage

Other

Mirabegron Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mirabegron Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Mirabegron Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mirabegron Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Mirabegron Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Mirabegron Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Mirabegron Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Mirabegron Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Mirabegron Drugs Industry Trends Table 2. Mirabegron Drugs Industry Drivers Table 3. Mirabegron Drugs Industry Opportunities and Challenges Table 4. Mirabegron Drugs Industry Restraints Table 5. Global Mirabegron Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Mirabegron Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Mirabegron Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Mirabegron Drugs Sales Market Share by Manufacturers Table 9. Global Mirabegron Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Mirabegron Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Mirabegron Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Mirabegron Drugs Manufacturers, Product Type & Application Table 13. Global Mirabegron Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Mirabegron Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Extended-release Tablet Table 17. Major Manufacturers of Oral Suspension Table 18. Global Mirabegron Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Mirabegron Drugs Sales by Type (2021-2026) & (K Units) Table 20. Global Mirabegron Drugs Sales by Type (2027-2032) & (K Units) Table 21. Global Mirabegron Drugs Sales Market Share by Type (2021-2026) Table 22. Global Mirabegron Drugs Sales Market Share by Type (2027-2032) Table 23. Global Mirabegron Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Mirabegron Drugs Revenue by Type (2021-2026) & (K Units) Table 25. Global Mirabegron Drugs Revenue by Type (2027-2032) & (K Units) Table 26. Global Mirabegron Drugs Revenue Market Share by Type (2021-2026) Table 27. Global Mirabegron Drugs Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Frequent Urination Table 29. Major Manufacturers of Urgency Table 30. Major Manufacturers of Urine Leakage Table 31. Major Manufacturers of Other Table 32. Global Mirabegron Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Mirabegron Drugs Sales by Application (2021-2026) & (K Units) Table 34. Global Mirabegron Drugs Sales by Application (2027-2032) & (K Units) Table 35. Global Mirabegron Drugs Sales Market Share by Application (2021-2026) Table 36. Global Mirabegron Drugs Sales Market Share by Application (2027-2032) Table 37. Global Mirabegron Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Mirabegron Drugs Revenue by Application (2021-2026) & (K Units) Table 39. Global Mirabegron Drugs Revenue by Application (2027-2032) & (K Units) Table 40. Global Mirabegron Drugs Revenue Market Share by Application (2021-2026) Table 41. Global Mirabegron Drugs Revenue Market Share by Application (2027-2032) Table 42. Global Mirabegron Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Mirabegron Drugs Sales by Region (2021-2026) & (K Units) Table 44. Global Mirabegron Drugs Sales Market Share by Region (2021-2026) Table 45. Global Mirabegron Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Mirabegron Drugs Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Mirabegron Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Mirabegron Drugs Sales by Country (2021-2026) & (K Units) Table 49. North America Mirabegron Drugs Sales by Country (2027-2032) & (K Units) Table 50. Europe Mirabegron Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Mirabegron Drugs Sales by Country (2021-2026) & (K Units) Table 52. Europe Mirabegron Drugs Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Mirabegron Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Mirabegron Drugs Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Mirabegron Drugs Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Mirabegron Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Mirabegron Drugs Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Mirabegron Drugs Sales by Country (2027-2032) & (K Units) Table 59. Global Mirabegron Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Mirabegron Drugs Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Mirabegron Drugs Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Mirabegron Drugs Revenue Market Share by Region (2021-2026) Table 63. Global Mirabegron Drugs Revenue Market Share by Region (2027-2032) Table 64. Alkem Laboratories Company Information Table 65. Alkem Laboratories Business Overview Table 66. Alkem Laboratories Mirabegron Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Alkem Laboratories Mirabegron Drugs Product Portfolio Table 68. Alkem Laboratories Recent Development Table 69. Astellas Pharma Company Information Table 70. Astellas Pharma Business Overview Table 71. Astellas Pharma Mirabegron Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Astellas Pharma Mirabegron Drugs Product Portfolio Table 73. Astellas Pharma Recent Development Table 74. Lupin Pharmaceuticals Company Information Table 75. Lupin Pharmaceuticals Business Overview Table 76. Lupin Pharmaceuticals Mirabegron Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Lupin Pharmaceuticals Mirabegron Drugs Product Portfolio Table 78. Lupin Pharmaceuticals Recent Development Table 79. Zydus Lifesciences Company Information Table 80. Zydus Lifesciences Business Overview Table 81. Zydus Lifesciences Mirabegron Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Zydus Lifesciences Mirabegron Drugs Product Portfolio Table 83. Zydus Lifesciences Recent Development Table 84. China Resources Pharmaceutical Company Information Table 85. China Resources Pharmaceutical Business Overview Table 86. China Resources Pharmaceutical Mirabegron Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. China Resources Pharmaceutical Mirabegron Drugs Product Portfolio Table 88. China Resources Pharmaceutical Recent Development Table 89. Jiangsu Huayang Pharmaceutical Company Information Table 90. Jiangsu Huayang Pharmaceutical Business Overview Table 91. Jiangsu Huayang Pharmaceutical Mirabegron Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Jiangsu Huayang Pharmaceutical Mirabegron Drugs Product Portfolio Table 93. Jiangsu Huayang Pharmaceutical Recent Development Table 94. Jiangxi Shanxiang Pharmaceutical Company Information Table 95. Jiangxi Shanxiang Pharmaceutical Business Overview Table 96. Jiangxi Shanxiang Pharmaceutical Mirabegron Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Jiangxi Shanxiang Pharmaceutical Mirabegron Drugs Product Portfolio Table 98. Jiangxi Shanxiang Pharmaceutical Recent Development Table 99. Qilu Pharmaceutical Company Information Table 100. Qilu Pharmaceutical Business Overview Table 101. Qilu Pharmaceutical Mirabegron Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Qilu Pharmaceutical Mirabegron Drugs Product Portfolio Table 103. Qilu Pharmaceutical Recent Development Table 104. Shenzhen Main Luck Pharmaceuticals Company Information Table 105. Shenzhen Main Luck Pharmaceuticals Business Overview Table 106. Shenzhen Main Luck Pharmaceuticals Mirabegron Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Shenzhen Main Luck Pharmaceuticals Mirabegron Drugs Product Portfolio Table 108. Shenzhen Main Luck Pharmaceuticals Recent Development Table 109. CSPC Pharmaceutical Company Information Table 110. CSPC Pharmaceutical Business Overview Table 111. CSPC Pharmaceutical Mirabegron Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. CSPC Pharmaceutical Mirabegron Drugs Product Portfolio Table 113. CSPC Pharmaceutical Recent Development Table 114. Sichuan Gowell Pharmaceutical Company Information Table 115. Sichuan Gowell Pharmaceutical Business Overview Table 116. Sichuan Gowell Pharmaceutical Mirabegron Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Sichuan Gowell Pharmaceutical Mirabegron Drugs Product Portfolio Table 118. Sichuan Gowell Pharmaceutical Recent Development Table 119. Zhejiang Huayi Pharmaceutical Company Information Table 120. Zhejiang Huayi Pharmaceutical Business Overview Table 121. Zhejiang Huayi Pharmaceutical Mirabegron Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Zhejiang Huayi Pharmaceutical Mirabegron Drugs Product Portfolio Table 123. Zhejiang Huayi Pharmaceutical Recent Development Table 124. Chia Tai Tianqing Pharmaceutical Company Information Table 125. Chia Tai Tianqing Pharmaceutical Business Overview Table 126. Chia Tai Tianqing Pharmaceutical Mirabegron Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Chia Tai Tianqing Pharmaceutical Mirabegron Drugs Product Portfolio Table 128. Chia Tai Tianqing Pharmaceutical Recent Development Table 129. Key Raw Materials Table 130. Raw Materials Key Suppliers Table 131. Mirabegron Drugs Distributors List Table 132. Mirabegron Drugs Customers List Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Mirabegron Drugs Product Image Figure 2. Global Mirabegron Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Mirabegron Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Mirabegron Drugs Sales (2021-2032) & (K Units) Figure 5. Global Mirabegron Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Mirabegron Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Extended-release Tablet Image Figure 9. Oral Suspension Image Figure 10. Global Mirabegron Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Mirabegron Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Mirabegron Drugs Sales Market Share by Type (2021-2032) Figure 13. Global Mirabegron Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Mirabegron Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Mirabegron Drugs Revenue Market Share by Type (2021-2032) Figure 16. Frequent Urination Image Figure 17. Urgency Image Figure 18. Urine Leakage Image Figure 19. Other Image Figure 20. Global Mirabegron Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Mirabegron Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Mirabegron Drugs Sales Market Share by Application (2021-2032) Figure 23. Global Mirabegron Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Mirabegron Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Mirabegron Drugs Revenue Market Share by Application (2021-2032) Figure 26. North America Mirabegron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Mirabegron Drugs Sales Market Share by Country (2021-2032) Figure 28. U.S. Mirabegron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Mirabegron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Mirabegron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Mirabegron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Mirabegron Drugs Sales Market Share by Country (2021-2032) Figure 33. Germany Mirabegron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Mirabegron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Mirabegron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Mirabegron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Mirabegron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Mirabegron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Mirabegron Drugs Sales Market Share by Country (2021-2032) Figure 40. China Mirabegron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Mirabegron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Mirabegron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Mirabegron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Mirabegron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Mirabegron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Mirabegron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Mirabegron Drugs Sales Market Share by Country (2021-2032) Figure 48. Brazil Mirabegron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Mirabegron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Mirabegron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Mirabegron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Mirabegron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Mirabegron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Mirabegron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Mirabegron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Mirabegron Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Mirabegron Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Mirabegron Drugs Revenue (2021-2032) & (US$ Million) Figure 59. North America Mirabegron Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Mirabegron Drugs Revenue (2021-2032) & (US$ Million) Figure 61. Europe Mirabegron Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Mirabegron Drugs Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Mirabegron Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Mirabegron Drugs Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Mirabegron Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Mirabegron Drugs Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Mirabegron Drugs Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Extended-release Tablet
  • Oral Suspension
Applications
  • Frequent Urination
  • Urgency
  • Urine Leakage
  • Other
Companies covered
  • Alkem Laboratories
  • Astellas Pharma
  • Lupin Pharmaceuticals
  • Zydus Lifesciences
  • China Resources Pharmaceutical
  • Jiangsu Huayang Pharmaceutical
  • Jiangxi Shanxiang Pharmaceutical
  • Qilu Pharmaceutical
  • Shenzhen Main Luck Pharmaceuticals
  • CSPC Pharmaceutical
  • Sichuan Gowell Pharmaceutical
  • Zhejiang Huayi Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Mirabegron Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Mirabegron Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Mirabegron Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Mirabegron Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Mirabegron Drugs Market Dynamics
  1. 2.1 Mirabegron Drugs Industry Trends
  2. 2.2 Mirabegron Drugs Industry Drivers
  3. 2.3 Mirabegron Drugs Industry Opportunities and Challenges
  4. 2.4 Mirabegron Drugs Industry Restraints
3 Mirabegron Drugs Market by Manufacturers
  1. 3.1 Global Mirabegron Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Mirabegron Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Mirabegron Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Mirabegron Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Mirabegron Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Mirabegron Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Mirabegron Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Mirabegron Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Mirabegron Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Mirabegron Drugs Tier 1, Tier 2, and Tier 3
4 Mirabegron Drugs Market by Type
  1. 4.1 Mirabegron Drugs Type Introduction
  2. 4.1.1 Extended-release Tablet
  3. 4.1.2 Oral Suspension
  4. 4.2 Global Mirabegron Drugs Sales by Type
  5. 4.2.1 Global Mirabegron Drugs Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Mirabegron Drugs Sales by Type (2021-2032)
  7. 4.2.3 Global Mirabegron Drugs Sales Market Share by Type (2021-2032)
  8. 4.3 Global Mirabegron Drugs Revenue by Type
  9. 4.3.1 Global Mirabegron Drugs Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Mirabegron Drugs Revenue by Type (2021-2032)
  11. 4.3.3 Global Mirabegron Drugs Revenue Market Share by Type (2021-2032)
5 Mirabegron Drugs Market by Application
  1. 5.1 Mirabegron Drugs Application Introduction
  2. 5.1.1 Frequent Urination
  3. 5.1.2 Urgency
  4. 5.1.3 Urine Leakage
  5. 5.1.4 Other
  6. 5.2 Global Mirabegron Drugs Sales by Application
  7. 5.2.1 Global Mirabegron Drugs Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Mirabegron Drugs Sales by Application (2021-2032)
  9. 5.2.3 Global Mirabegron Drugs Sales Market Share by Application (2021-2032)
  10. 5.3 Global Mirabegron Drugs Revenue by Application
  11. 5.3.1 Global Mirabegron Drugs Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Mirabegron Drugs Revenue by Application (2021-2032)
  13. 5.3.3 Global Mirabegron Drugs Revenue Market Share by Application (2021-2032)
6 Global Mirabegron Drugs Sales by Region
  1. 6.1 Global Mirabegron Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Mirabegron Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Mirabegron Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Mirabegron Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Mirabegron Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Mirabegron Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Mirabegron Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Mirabegron Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Mirabegron Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Mirabegron Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Mirabegron Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Mirabegron Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Mirabegron Drugs Revenue by Region
  1. 7.1 Global Mirabegron Drugs Revenue by Region
  2. 7.1.1 Global Mirabegron Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Mirabegron Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Mirabegron Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Mirabegron Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Mirabegron Drugs Revenue (2021-2032)
  8. 7.2.2 North America Mirabegron Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Mirabegron Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Mirabegron Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Mirabegron Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Mirabegron Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Mirabegron Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Mirabegron Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Alkem Laboratories
  2. 8.1.1 Alkem Laboratories Company Information
  3. 8.1.2 Alkem Laboratories Business Overview
  4. 8.1.3 Alkem Laboratories Mirabegron Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Alkem Laboratories Mirabegron Drugs Product Portfolio
  6. 8.1.5 Alkem Laboratories Recent Developments
  7. 8.2 Astellas Pharma
  8. 8.2.1 Astellas Pharma Company Information
  9. 8.2.2 Astellas Pharma Business Overview
  10. 8.2.3 Astellas Pharma Mirabegron Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Astellas Pharma Mirabegron Drugs Product Portfolio
  12. 8.2.5 Astellas Pharma Recent Developments
  13. 8.3 Lupin Pharmaceuticals
  14. 8.3.1 Lupin Pharmaceuticals Company Information
  15. 8.3.2 Lupin Pharmaceuticals Business Overview
  16. 8.3.3 Lupin Pharmaceuticals Mirabegron Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Lupin Pharmaceuticals Mirabegron Drugs Product Portfolio
  18. 8.3.5 Lupin Pharmaceuticals Recent Developments
  19. 8.4 Zydus Lifesciences
  20. 8.4.1 Zydus Lifesciences Company Information
  21. 8.4.2 Zydus Lifesciences Business Overview
  22. 8.4.3 Zydus Lifesciences Mirabegron Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Zydus Lifesciences Mirabegron Drugs Product Portfolio
  24. 8.4.5 Zydus Lifesciences Recent Developments
  25. 8.5 China Resources Pharmaceutical
  26. 8.5.1 China Resources Pharmaceutical Company Information
  27. 8.5.2 China Resources Pharmaceutical Business Overview
  28. 8.5.3 China Resources Pharmaceutical Mirabegron Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 China Resources Pharmaceutical Mirabegron Drugs Product Portfolio
  30. 8.5.5 China Resources Pharmaceutical Recent Developments
  31. 8.6 Jiangsu Huayang Pharmaceutical
  32. 8.6.1 Jiangsu Huayang Pharmaceutical Company Information
  33. 8.6.2 Jiangsu Huayang Pharmaceutical Business Overview
  34. 8.6.3 Jiangsu Huayang Pharmaceutical Mirabegron Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Jiangsu Huayang Pharmaceutical Mirabegron Drugs Product Portfolio
  36. 8.6.5 Jiangsu Huayang Pharmaceutical Recent Developments
  37. 8.7 Jiangxi Shanxiang Pharmaceutical
  38. 8.7.1 Jiangxi Shanxiang Pharmaceutical Company Information
  39. 8.7.2 Jiangxi Shanxiang Pharmaceutical Business Overview
  40. 8.7.3 Jiangxi Shanxiang Pharmaceutical Mirabegron Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Jiangxi Shanxiang Pharmaceutical Mirabegron Drugs Product Portfolio
  42. 8.7.5 Jiangxi Shanxiang Pharmaceutical Recent Developments
  43. 8.8 Qilu Pharmaceutical
  44. 8.8.1 Qilu Pharmaceutical Company Information
  45. 8.8.2 Qilu Pharmaceutical Business Overview
  46. 8.8.3 Qilu Pharmaceutical Mirabegron Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Qilu Pharmaceutical Mirabegron Drugs Product Portfolio
  48. 8.8.5 Qilu Pharmaceutical Recent Developments
  49. 8.9 Shenzhen Main Luck Pharmaceuticals
  50. 8.9.1 Shenzhen Main Luck Pharmaceuticals Company Information
  51. 8.9.2 Shenzhen Main Luck Pharmaceuticals Business Overview
  52. 8.9.3 Shenzhen Main Luck Pharmaceuticals Mirabegron Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Shenzhen Main Luck Pharmaceuticals Mirabegron Drugs Product Portfolio
  54. 8.9.5 Shenzhen Main Luck Pharmaceuticals Recent Developments
  55. 8.10 CSPC Pharmaceutical
  56. 8.10.1 CSPC Pharmaceutical Company Information
  57. 8.10.2 CSPC Pharmaceutical Business Overview
  58. 8.10.3 CSPC Pharmaceutical Mirabegron Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 CSPC Pharmaceutical Mirabegron Drugs Product Portfolio
  60. 8.10.5 CSPC Pharmaceutical Recent Developments
  61. 8.11 Sichuan Gowell Pharmaceutical
  62. 8.11.1 Sichuan Gowell Pharmaceutical Company Information
  63. 8.11.2 Sichuan Gowell Pharmaceutical Business Overview
  64. 8.11.3 Sichuan Gowell Pharmaceutical Mirabegron Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Sichuan Gowell Pharmaceutical Mirabegron Drugs Product Portfolio
  66. 8.11.5 Sichuan Gowell Pharmaceutical Recent Developments
  67. 8.12 Zhejiang Huayi Pharmaceutical
  68. 8.12.1 Zhejiang Huayi Pharmaceutical Company Information
  69. 8.12.2 Zhejiang Huayi Pharmaceutical Business Overview
  70. 8.12.3 Zhejiang Huayi Pharmaceutical Mirabegron Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Zhejiang Huayi Pharmaceutical Mirabegron Drugs Product Portfolio
  72. 8.12.5 Zhejiang Huayi Pharmaceutical Recent Developments
  73. 8.13 Chia Tai Tianqing Pharmaceutical
  74. 8.13.1 Chia Tai Tianqing Pharmaceutical Company Information
  75. 8.13.2 Chia Tai Tianqing Pharmaceutical Business Overview
  76. 8.13.3 Chia Tai Tianqing Pharmaceutical Mirabegron Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Chia Tai Tianqing Pharmaceutical Mirabegron Drugs Product Portfolio
  78. 8.13.5 Chia Tai Tianqing Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Mirabegron Drugs Value Chain Analysis
  2. 9.1.1 Mirabegron Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Mirabegron Drugs Production Mode & Process
  6. 9.2 Mirabegron Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Mirabegron Drugs Distributors
  9. 9.2.3 Mirabegron Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst